Last updated on February 2019

Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis


Brief description of study

This post-marketing study is designed to compare the safety of tofacitinib versus TNF inhibitor with respect to major cardiovascular adverse events and malignancies, excluding non-melanoma skin cancers when given to subjects with rheumatoid arthritis. Other safety events, including non-melanoma skin cancers, hepatic events, infections, and efficacy parameters will be collected and evaluated in the study.

Clinical Study Identifier: NCT02092467

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Keck Medicine of USC
Los Angeles, CA United States
8.18miles
  Connect »

Pfizer CT.gov Call Center

University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, CA United States
8.18miles
  Connect »

Pfizer CT.gov Call Center

Investigational Drug Service
Torrance, CA United States
8.41miles
  Connect »

Pfizer CT.gov Call Center

Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
Torrance, CA United States
8.41miles
  Connect »

Pfizer CT.gov Call Center

Valerius Medical Group And Research Center Of Greater Long Beach, Inc.
Long Beach, CA United States
8.8miles
  Connect »

Pfizer CT.gov Call Center

ProHealth Partners
Long Beach, CA United States
9.35miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.